159596-55-1Relevant academic research and scientific papers
Design and SAR of novel potassium channel openers targeted for urge urinary incontinence. 1. N-cyanoguanidine bioisosteres possessing in vive bladder selectivity
Butera, John A.,Antane, Madelene M.,Antane, Schuyler A.,Argentieri, Thomas M.,Freeden, Chris,Graceffa, Russell F.,Hirth, Bradford H.,Jenkins, Douglas,Lennox, Joseph R.,Matelan, Edward,Norton, N. Wesley,Quagliato, Dominick,Sheldon, Jeffrey H.,Spinelli, Walter,Warga, Dawn,Wojdan, Alexandra,Woods, Morgan
, p. 1187 - 1202 (2000)
A structurally novel series of adenosine 5'-triphosphate-sensitive potassium (K(ATP)) channel openers is described. As part of our efforts directed toward identifying novel, bladder-selective potassium channel openers (KCOs) targeted for urge urinary incontinence (UUI), we found that bioisosteric replacement of the N-cyanoguanidine moiety of pinacidil (1, Figure 1) with a diaminocyclobutenedione template afforded squaric acid analogue 2, the prototype of a novel series of K(ATP) channel openers with unique selectivity for bladder smooth muscle in vive. Further modification of the heterocyclic ring to give substituted aryl derivatives (3) afforded potent KCOs that possessed the desired detrusor selectivity when administered orally. The effects of these potassium channel agonists on bladder contractile function was studied in vitro using isolated rat detrusor strips. Potent relaxants were evaluated in vive in a rat model of bladder instability. Lead compounds were evaluated concomitantly in normotensive rats for their effects on mean arterial blood pressure (MAP) and heart rate as a measure of in vive bladder selectivity. (R)-4-[3,4-Dioxo-2-(1,2,2-trimethyl- propylamino)-cyclobut-1-enyαmino]-3-ethyl-benzonitrile (79) met our potency and selectivity criteria and represents an attractive development candidate for the treatment of UUI. Electrophysiological studies using isolated rat bladder detrusor myocytes have demonstrated that compound 79 produces significant hyperpolarization which is glyburide-reversed, thus consistent with the activation of K(ATP). The design, synthesis, structure-activity relationships (SAR), and pharmacological activity associated with this series of novel KCOs will be discussed.
Diaminocyclobutene-3,4-diones
-
, (2008/06/13)
The compound of the formula: STR1 wherein: R1 and R2 are, independent from each other, hydrogen, C1-10 straight chain alkyl, C1-10 branched alkyl, or C3-10 cyclic or bicyclic alkyl; R3 is a
Diaminocyclobutene-3,4-diones
-
, (2008/06/13)
The compounds of formula I: STR1 wherein R1 and R2 are hydrogen, alkyl or cyclic or bicyclic alkyl; R3 is formyl, alkanoyl, alkenoyl, alkylsulfonyl, aroyl, arylalkenoyl, arylsulfonyl arylalkanoyl or arylalkylsulfonyl; A is
Substituted N-heteroaryl and N-aryl-1,2-diaminocyclobutene-3,4-diones
-
, (2008/06/13)
The compounds of the formula: STR1 wherein: R1 and R2 are, independently, hydrogen, straight or branched chain alkyl or mono- or bi-cyclic alkyl; A is a substituted phenyl group containing one cyano substituent and one substituent se
Diaminocyclobutene-3,4-diones
-
, (2008/06/13)
The compound of the formula (I) or a pharmaceutically acceptable salt thereof, are smooth muscle relaxants. STR1
Substituted n-aryl-1,2-diaminocyclobutene-3,4-diones
-
, (2008/06/13)
The compound of the formula (I) or a pharmaceutically acceptable salt thereof, are smooth muscle relaxants STR1
Substituted N-heteroaryl and N-aryl-1,2-diaminocyclobutene-3,4-diones
-
, (2008/06/13)
The compounds of the formula: STR1 wherein: R1 and R2 are, independently, hydrogen, straight or branched chain alkyl or mono- or bi-cyclic alkyl; A is an N-heterocycle which may be substituted by alkyl, perfluoroalkyl, alkoxy, perflu
